SHARE

New Research Report by Researchstore.biz on “Global Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market by Procedure (Transapical, Transfemoral, Transaortic), Region (North America, Europe, Asia Pacific, South America and Middle East and Africa)” and Global Forecast 2018-2025, presents the worldwide Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) market size.

The global transcatheter aortic valve replacement/implantation (TAVR/TAVI) market valued USD 3.67 Billion in 2017 and is projected to hold USD 6.86 Billion by 2025 at a CAGR of a 7.11% during the forecast period from 2018-2025. Prominent drivers that fuel the growth of transcatheter aortic valve replacement/implantation (TAVR/TAVI) market are:

  • The rising prevalence of severe aortic stenosis and asymptomatic
  • Developments in the transcatheter aortic valves and increase in the adoption rate of TAVI devices
  • Increasing incidence of cardiovascular diseases
  • Growing demand for minimally invasive surgeries

Market Inspection:

The transcatheter aortic valve replacement/implantation (TAVI/TAVR) process are used to develop and replace an aortic valve. This process offers an effective option in contrast to cumbersome open heart medical procedure. Particularly developed for high-risk patients, the system reduces serious degenerative aortic stenosis and increasing survival rate of patients. TAVR is used in the treatment of high-risk patients suffering from aortic stenosis. In this process, transcatheter aortic valves are implanted to redevelop the blood circulation ability of the aortic valve. The TAVI valve is fixed within the contaminated aortic valve.

DOWNLOAD FREE SAMPLE REPORT:https://researchstore.biz/report/global-transcatheter-aortic-valve-replacement-implantation-tavr-tavi-market/71603/#requestforsample

An increasing prevalence of severe aortic stenosis and asymptomatic and increasing incidence of cardiovascular diseases to drive transcatheter aortic valve replacement/implantation (TAVR/TAVI) market:

The transcatheter aortic valve replacement/implantation (TAVR/TAVI) market is driven by the following key factors:

Increasing demand for minimally invasive surgeries

The increasing prevalence of severe aortic stenosis

Asymptomatic and increasing incidence of cardiovascular diseases

The growth restraining factors for the market are:

The strict government regulations for approval of transcatheter aortic valves

The high cost associated with TAVI

However, use of TAVI systems for new indications, rise in healthcare expenditure in emerging economies would enhance the transcatheter aortic valve replacement/implantation (TAVR/TAVI) market over the forecast period.

ACCESS FULL REPORT:https://researchstore.biz/report/global-transcatheter-aortic-valve-replacement-implantation-tavr-tavi-market/71603/

Segmentation Coverage:

The global transcatheter aortic valve replacement/implantation (TAVR/TAVI) market is segmented on the basis of procedure and regions.

Transfemoral segment valued around USD 1.33 Billion in 2017

On the basis of procedure, this market is segmented into transapical, transfemoral, and transaortic segment. Transfemoral segment is projected to grow with the highest CAGR over the forecast period. The key factors that will drive the demand of transfemoral segment include the adoption by a number of doctors due to its positive outcomes of TAVR/TAVI and increase in the prevalence of aortic stenosis coupled with increase in geriatric population.

Regional Segmentation Analysis:

The major segments included in the market are North America, Europe, Asia Pacific, South America, and the Middle East and Africa. In 2017, North America held the largest market share of approximately 31.11%. The high adoption of technologically advanced products is one of the most leading factors that led to the growth of transcatheter aortic valve replacement/implantation (TAVR/TAVI) market in this region.

Market competition by top players covers following key players:

Abbott Laboratories, Boston Scientific Corporation, JC Medical, Inc., Medtronic plc., NVT AG, Bracco S.p.A., Edwards Lifesciences Corporation, JenaValve Technology, Inc., Meril Life Sciences Pvt. Ltd., Transcatheter Technologies GmbH, SYMETIS, Braile Biomedica, Venus Medtech, Inc., and others.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@researchstore.biz), who will ensure that you get a report that suits your needs.